Company Number: 14830299

Analysis Date: 2025-07-19 12:05 UTC

Financial Health Assessment Report: SM PHARMCO LIMITED

---

1. Financial Health Score: D (Poor)

Explanation:
SM Pharmco Limited shows significant signs of financial distress based on its latest available financial data. The company has a highly negative working capital position and minimal equity base, indicating liquidity challenges and potential solvency concerns. While the company is in its infancy (incorporated in 2023), the current financial "vital signs" suggest urgent attention is required to restore financial health.

---

2. Key Vital Signs

Metric	Value (£)	Interpretation
Current Assets	159,635	Cash and receivables indicate some liquidity present but not sufficient to cover liabilities.
Cash	109,732	Healthy cash presence relative to assets, but insufficient for current obligations.
Debtors	49,903	Receivables exist but are not readily convertible to cash immediately.
Current Liabilities	360,635	Liabilities due within one year; significantly larger than current assets—red flag for liquidity.
Net Current Assets (Working Capital)	-201,000	Negative working capital indicates inability to cover short-term debts with short-term assets.
Total Assets Less Current Liabilities	2	Virtually zero net asset value, signaling minimal equity buffer and potential insolvency risk.
Shareholders’ Funds (Equity)	2	Extremely low equity base, suggesting very limited financial cushion or capital invested.

Additional Observations:

• Fixed asset investment of £201,002 exists; however, this is offset by large current liabilities.
• The company has loans receivable from related entities (£49,902), interest-free and repayable on demand, which are current assets but may not be immediately liquid.
• The company is exempt from audit, typical for small companies, but less transparency might pose risks.
• Directors hold significant control with equal shareholding and voting rights.

---

3. Diagnosis: Financial Condition and Symptoms

• Liquidity Crisis: The company exhibits symptoms akin to a patient with a dangerously low level of blood pressure (cash flow) relative to its obligations. Negative working capital of £201,000 signals that SM Pharmco Limited currently lacks the liquid assets to meet its short-term debts, which is a critical symptom of financial distress.

• Solvency Concerns: With shareholders’ funds at only £2, the company’s equity cushion is effectively non-existent. This suggests the company is "financially anaemic," relying heavily on short-term liabilities. The total assets less current liabilities of just £2 further underscore a fragile solvency position.

• Risk of Insolvency: The imbalance between current liabilities and assets, coupled with minimal equity, indicates a risk that the company may struggle to continue as a going concern without additional capital injection or debt restructuring.

• Potential Related Party Dependency: Significant amounts are due from related companies, which may not be immediately collectible, potentially exacerbating liquidity issues if these related entities also face financial difficulties.

• Early Stage Growth Challenges: Given the company was incorporated in April 2023 and the latest accounts cover only a four-month period ending August 2024, it is plausible that the company is still in a startup phase with initial investments and setup costs outweighing revenues.

---

4. Recommendations: Prescriptions for Financial Wellness

• Urgent Cash Flow Management: Immediate focus should be on improving liquidity. This could include accelerating debtor collections, negotiating extended payment terms with creditors, or converting related party loans into cash to relieve short-term pressures.

• Capital Injection: Directors and shareholders should consider injecting additional equity capital to build a stronger financial buffer, reduce dependence on short-term liabilities, and improve solvency.

• Debt Restructuring: Engage creditors in discussions to restructure or extend payment terms on current liabilities to avoid default and ease liquidity stress.

• Monitor Related Party Balances: Closely monitor recoverability of loans from related parties. If these are unlikely to be repaid promptly, the company should seek alternative liquidity sources.

• Financial Reporting and Controls: Though exempt from audit, establishing robust internal financial controls and regular cash flow forecasting will help detect and address financial issues proactively.

• Strategic Review: Directors should review business strategy to ensure sustainable revenue generation and cost control to move towards profitability and improve net asset position.

---

Medical Analogy Summary

SM Pharmco Limited currently exhibits "symptoms of financial distress" with a dangerously low "blood pressure" (liquidity) and "weak pulse" (equity). Without prompt "treatment" in the form of capital infusion, cash flow improvement, and liability management, the company risks "collapse" (insolvency). However, as a young company, there is potential for recovery if the right "medical interventions" are applied swiftly.

---